Details for Patent: RE44733
✉ Email this page to a colleague
Which drugs does patent RE44733 protect, and when does it expire?
Patent RE44733 protects BRIDION and is included in one NDA.
This patent has forty-two patent family members in thirty countries.
Summary for Patent: RE44733
| Title: | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
| Abstract: | Disclosed is a 6-mercapto-cyclodextrin derivative having general formula (I) wherein m is 0-7 and n is 1-8 and m+n=7 or 8; R is (C.sub.1-6)alkylene, optionally substituated with 1-3 OH groups, or (CH.sub.2).sub.o-phenylene-(CH.sub.2).sub.p--; o and p are independently 0-4; X is COOH, CONHR.sub.1, NHCOR.sub.2, SO.sub.2OH, PO(OH).sub.2, O(CH.sub.2--CH.sub.2--O).sub.q--H, OH or tetrazol-5-yl; R.sub.1 is H or (C.sub.1-3)alkyl; R.sub.2 is carboxyphenyl; q is 1-3; or pharmaceutically acceptable salts thereof. The 6-mercaptocyclodextrin derivative is highly suitable for use in the reversal of drug-induced neuromuscular block. ##STR00001## |
| Inventor(s): | Zhang; Mingiang (Montreal, CA), Palin; Ronald (Banton, GB), Bennett; Jonathan (Edinburgh, GB) |
| Assignee: | Merck Sharp & Dohme B.V. (Haarlem, NL) |
| Application Number: | 13/432,742 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent RE44733 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Device; Use; |
Drugs Protected by US Patent RE44733
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-002 | Dec 15, 2015 | AP | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK | ⤷ Sign Up | |
| Msd Sub Merck | BRIDION | sugammadex sodium | SOLUTION;INTRAVENOUS | 022225-001 | Dec 15, 2015 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK | ⤷ Sign Up | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: RE44733
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 99309558 | Nov 29, 1999 | |
| PCT Information | |||
| PCT Filed | November 23, 2000 | PCT Application Number: | PCT/EP00/11789 |
| PCT Publication Date: | June 07, 2001 | PCT Publication Number: | WO01/40316 |
International Family Members for US Patent RE44733
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1259550 | ⤷ Sign Up | 91501 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1259550 | ⤷ Sign Up | CA 2009 00002 | Denmark | ⤷ Sign Up |
| European Patent Office | 1259550 | ⤷ Sign Up | 300356 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1259550 | ⤷ Sign Up | SPC031/2008 | Ireland | ⤷ Sign Up |
| European Patent Office | 1259550 | ⤷ Sign Up | 08C0052 | France | ⤷ Sign Up |
| European Patent Office | 1259550 | ⤷ Sign Up | C01259550/01 | Switzerland | ⤷ Sign Up |
| European Patent Office | 1259550 | ⤷ Sign Up | SPC/GB08/057 | United Kingdom | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
